Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer

Figure 1 Kaplan-Meier estimates of progression-free survival and overall survival, according to treatment groups. A: Shows progression-free survival; median was 2.0 mo in the group received capecitabine, 2.7 mo in the group received S-1; B: Shows overall survival; the median was 4.3 mo in the capecitabine group and 5.0 mo in the S-1 group.

Figure 2 Kaplan-Meier curves of progression-free survival and overall survival according to 5-fluorouracil exposure in each treatment group. A, B: progression-free survival in capecitabine group and S-1 group according to 5-fluorouracil exposure; C, D: overall survival analysis in capecitabine group and S-1 group according to 5-fluorouracil exposure.